Unit, direct support, and general support maintenance repair parts and special tools lists ... : crane-shovel, crawler mounted, 12-1/2-ton, 3/4 cu yd, diesel engine driven, NSN 3810-00-869-3092 : Bucyrus-Erie model 22BM.

"April 1992."

Direct support and general support maintenance repair parts and special tools list ... for interrogator set AN/TPX-46(V)1, 2, 3, 4, and 6, control, antenna C-8738/TPX-46(V) (NSN 5895-00-141-3606), antenna-radome ... pedestal, antenna ....

"5 December 1980."

Fragm. lat. III 34 - Liber Sextus Decretalium (1.4.1 - 4; 1.6.43 - 46; 1.22.2 - 3.3; 3.4.23 - 24), ohne Glosse

Trägerband: Inc. qu. 738; Inc. qu. 913; 'Vocabularius Ex quo'; Vorbesitzer: Dominikanerkloster Frankfurt am Main

Studies on the neurotoxicity of 6,7-dihydroxy-1-methyl-1,2,3,4-tetrahydroisoquinoline (salsolinol) in SH-SY5Y cells

We have studied the hypothesis that 6,7-dihydroxy-1-methyl-1,2,3,4-tetrahydroisoquinoline (salsolinol) is neurotoxic. Salsolinol induced a significant time and dose related inhibition of 3[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide; thiazoyl blue (MTT) reduction, and increased lactate dehydrogenase release (LDH) release from human SH-SY5Y neuroblastoma cells, at concentrations within the range of 1-methyl-4-phenylpyridinium (MPP+) cytotoxicity, in vitro. Cytotoxicity was not inhibited by the addition of antioxidants, monoamine oxidase inhibitors or imipramine. In confluent monolayers, salsolinol stimulated catecholamine uptake with EC50 values of 17 muM and 11 muM, for noradrenaline and dopamine, respectively. Conversely, at concentrations above 100 muM, salsolinol inhibited the uptake of noradrenaline and dopamine, with IC50 values of 411 muM and 379 muM, respectively. The inhibition of catecholamine uptake corresponded to the increase displacement of [3H]nisoxetine from the uptake 1 site by salsolinol, as the Ki (353 muM) for displacement was similar to the IC50 (411 and 379 muM) for uptake. Salsolinol stimulated catecholamine uptake does not involve the uptake recognition site, or elevation of cAMP, cGMP, or inhibition of protein kinase C. Salsolinol also inhibited both carbachol (1 mM) and K+ (100 mM, Na+ adjusted) evoked released of noradrenaline from SH-SY5Y cells, with IC50 values of 500 muM and 120 muM, respectively. In conclusion, salsolinol appears to be cytotoxic to SH-SY5Y cells, via a mechanism that does not require uptake 1, bioactivation by monoamine oxidase, or membrane based free radical damage. The effects of salsolinol on catecholamine uptake, and the mechanism of toxicity require further investigation.

Síntese de novas 3,4-diidropirimidin-2(1H)-onas graxas e estudo da atividade antitumoral

Neste trabalho foi realizada a síntese de novas 3,4-diidropirimidinonas funcionalizadas com diferentes cadeias graxas. Para a síntese destes compostos os β-cetoésteres graxos foram obtidos a partir da transesterificação do acetoacetato de metila na presença dos álcoois palmítico (2a), esteárico (2b) e oleico (2c), utilizando como catalisador I2 e ácido sulfâmico (NH3SO3). Os compostos foram obtidos com rendimentos de 97%, 90% e 60%, respectivamente. Após, a reação multicomponente de Biginelli foi realizada na presença de InCl3 utilizando os β- cetoésteres graxos 3a-c, os aldeídos aromáticos, benzaldeído, 3-hidroxi benzaldeído e 4-dimetilaminobenzaldeído, na presença de uréia ou tiouréia, levando às 3,4- diidropirimidinonas graxas 5-substituídas 6-11a-c em rendimentos que variaram entre 60–94%. Todos os compostos, ainda inéditos na literatura, foram caracterizados por espectroscopia de infravermelho (IV) e ressonância magnética nuclear de hidrogênio (RMN ¹H) e carbono (RMN ¹³C). A análise do efeito das novas 3,4-diidropirimidin-2(1H)-onas graxas pelo método do MTT na linhagem de glioma C6 rato e UG-138 humana demonstrou uma maior diminuição da viabilidade celular para os compostos graxos contendo as cadeias palmítica e oleica derivados da tiouréia e do 3-hidroxi benzaldeído, respectivamente. Comportamento semelhante foi observado para os compostos contendo as cadeias palmítica e oleica, porém derivados da uréia. Uma diminuição significativa da viabilidade celular, porém em menor grau, foi observada para os compostos graxos contendo as cadeias palmítica e oleica derivados da uréia e do benzaldeído. Os resultados mostraram até o momento que os derivados graxos contendo a cadeia oleica na posição 5 do anel diidropirimídinico derivado do 3- hidroxi benzaldeído e da tiouréia apresentaram maior atividade na diminuição da viabilidade celular de linhagem de glioma.

Desenvolvimento e validação de metodologias para quantificação de 3,4 metilenodioximetanfetamina (MDMA) em comprimidos de ecstasy por cromatografia gasosa e ressonância magnética nuclear

Dissertação (mestrado)—Universidade de Brasília, Instituto de Química, 2016.

Practice and procedure : a recent Court of Appeal case examines the meaning of 'third party payer' in terms of Part 3.4 of the Legal Profession Act 2007.

In Legal Services Commissioner v Wright [2010] QCA 321 the Queensland Court of Appeal allowed an appeal from the first instance decision. The decision involved the construction of “third party payer” in Part 3.4 of the Legal Profession Act 2007 (Qld).

Preliminary evaluation of a primary care intervention for cry-fuss behaviours in the first 3-4 months of life (‘The Possums Approach’) : effects on cry-fuss behaviours and maternal mood

Problem crying in the first few months of life is both common and complex, arising out of multiple interacting and co-evolving factors. Parents whose babies cry and fuss a lot receive conflicting advice as they seek help from multiple health providers and emergency departments, and may be admitted into tertiary residential services. Conflicting advice is costly, and arises out of discipline-specific interpretations of evidence. An integrated, interdisciplinary primary care intervention (‘The Possums Approach’) for cry-fuss problems in the first months of life was developed from available peer-reviewed evidence. This study reports on preliminary evaluation of delivery of the intervention. A total of 20 mothers who had crying babies under 16 weeks of age (average age 6.15 weeks) completed questionnaires, including the Crying Patterns Questionnaire and the Edinburgh Postnatal Depression Scale, before and 3-4 weeks after their first consultation with trained primary care practitioners. Preliminary evaluation is promising. The Crying Patterns Questionnaire showed a significant decrease in crying and fussing duration, by 1 h in the evening (P = 0.001) and 30 min at night (P = 0.009). The median total amount of crying and fussing in a 24-h period was reduced from 6.12 to 3 h. The Edinburgh Postnatal Depression Scale showed a significant improvement in depressive symptoms, with the median score decreasing from 11 to 6 (P = 0.005). These findings are corroborated by an analysis of results for the subset of 16 participants whose babies were under 12 weeks of age (average age 4.71 weeks). These preliminary results demonstrate significantly decreased infant crying in the evening and during the night and improved maternal mood, validating an innovative interdisciplinary clinical intervention for cry-fuss problems in the first few months of life. This intervention, delivered by trained health professionals, has the potential to mitigate the costly problem of health professionals giving discipline-specific and conflicting advice post-birth.

Poly-[μ-aqua-μ5-[(2,3,6-trichlorophenyl)acetato)-caesium]

In the structure of the title complex [Cs(C8H4Cl3O2)(H2O)]n, the Cs salt of the commercial herbicide fenac [(2,3,6-trichlorophenyl)acetic acid], the irregular eight-coordination about Cs+ comprises a bidentate chelate (O:Cl) interaction involving a carboxyl O-atom and an ortho-related ring substituted Cl atom which is also bridging, a triple-bridging carboxyl O-atom and a bridging water molecule. A two-dimensional sheet polymer is generated, lying parallel to (100), within which there are water O---H...O(carboxyl) hydrogen-bonding interactions.

A 5- versus 3-day course of oral corticosteroids for children with asthma exacerbations who are not hospitalised : a randomised controlled trial

Objective To determine whether a 5-day course of oral prednisolone is superior to a 3-day course in reducing the 2-week morbidity of children with asthma exacerbations who are not hospitalised. Design, setting and participants Double-blind randomised controlled trial of asthma outcomes following a 5-day course of oral prednisolone (1 mg/kg) compared with a 3-day course of prednisolone plus placebo for 2 days. Participants were children aged 2–15 years who presented to the emergency departments of three Queensland hospitals between March 2004 and February 2007 with an acute exacerbation of asthma, but were not hospitalised. Sample size was defined a priori for a study power of 90%. Main outcome measures Difference in proportion of children who were symptom-free at Day 7, as measured by intention-to-treat (ITT) and per-protocol analysis; quality of life (QOL) on Days 7 and 14. Results 201 children were enrolled, and there was an 82% completion rate. There was no difference between groups in the proportion of children who were symptom-free (observed difference, 0.04 [95% CI, − 0.09 to 0.18] by ITT analysis; 0.04 [95% CI, − 0.17 to 0.09] by per-protocol analysis). There was also no difference between groups in QOL (P = 0.42). The difference between groups for the primary outcome was within the equivalence range calculated post priori. Conclusion A 5-day course of oral prednisolone confers no advantage over a 3-day course for children with asthma exacerbations who are not hospitalised.

3,6-Di(furan-2-yl)pyrrolo[3,4-c]pyrrole-1,4(2H,5H)-dione and bithiophene copolymer with rather disordered chain orientation showing high mobility in organic thin film transistors

Pyrrolo[3,4-c]pyrrole-1,4(2H,5H)-dione or diketopyrrolopyrrole (DPP) is a useful electron-withdrawing fused aromatic moiety for the preparation of donor-acceptor polymers as active semiconductors for organic electronics. This study uses a DPP-furan-containing building block, 3,6-di(furan-2-yl)pyrrolo[3,4- c]pyrrole-1,4(2H,5H)-dione (DBF), to couple with a 2,2′-bithiophene unit, forming a new donor-acceptor copolymer, PDBFBT. Compared to its structural analogue, 3,6-di(thiophen-2-yl)pyrrolo[3,4-c]pyrrole-1,4(2H,5H)-dione (DBT), DBF is found to cause blue shifts of the absorption spectra both in solution and in thin films and a slight reduction of the highest occupied molecular orbital (HOMO) energy level of the resulting PDBFBT. Despite the fact that its thin films are less crystalline and have a rather disordered chain orientation in the crystalline domains, PDBFBT shows very high hole mobility up to 1.54 cm 2 V-1 s-1 in bottom-gate, top-contact organic thin film transistors.